Health Catalyst dropped about 25% to US$1.73 after its latest report, even though the headline numbers were not a collapse story. Q2 revenue landed at US$70.5 million and adjusted EBITDA came in at US$9.9 million, with adjusted EPS at US$0.04. The real jolt came from what happens next. The sale of the higher margin Vitalware unit, the shift to the Ignite platform and fresh guidance all reshape the earnings path from here.

Investors may appreciate the recurring software revenue at Health Catalyst but could also be concerned about the changing margin profile following the Vitalware sale and Ignite transition. Take a look at our curated list of stocks with stronger profitability trends and balance sheets in the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$70.5m vs. US$80.7m (revenue declined about 13%)
• Net Loss, Q2 2026 vs. Q2 2025: US$40.5m loss vs. US$41.0m loss (loss slightly improved)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.55 loss per share vs. US$0.59 loss per share (per share loss narrowed)
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$9.9m vs. prior period not disclosed (latest result is within the management guidance range)

Prefer clear visuals instead of pages of earnings tables and footnotes? Get a full picture of Health Catalyst with an at a glance view of its valuation in the company report for Health Catalyst..

Health Catalyst Bull Case Meets Mixed Execution Milestones

Bulls argue Health Catalyst can use the Ignite platform and higher margin applications to lift profitability while growing its client base. The latest quarter partially supports this. Technology revenue at US$48.8m and adjusted technology gross margin in the low 60s indicate the core software engine is still contributing most of the economics, even as migration work and deployment costs weigh on margins. Adjusted operating expenses at US$25.9m, or 37% of revenue, and adjusted EBITDA of US$9.9m within guidance indicate some early operating discipline.

However, several key milestones for the bullish story remain unproven. Management expects full year adjusted gross margin below 50% and Q3 EBITDA around breakeven, which does not yet reflect margin lift from Ignite cross sells. The unchanged US$22m to US$26m bookings target suggests pipeline health, but there is no clear inflection yet in higher margin application adoption.

Compare Health Catalyst's internal progress on Ignite margins and cost control with external expectations. See the consensus price target analysis for Health Catalyst to check how closely Wall Street price targets line up with this bullish thesis.

Health Catalyst Bears See Revenue Headwinds Confirmed

The bearish view on Health Catalyst centers on multi year demand weakness and a tougher mix shift as services shrink faster than software ramps. The latest quarter gives that concern some support. Total revenue of US$70.5m sits against guidance that now calls for full year revenue of US$246m to US$249m, which factors in a sharp step down to US$55m to US$56m in Q3. That aligns with fears that client budget cuts and smaller deal sizes are weighing on growth just as professional services are under review.

Bears also worry that execution on Project Nexus and the Vitalware sale might not quickly rebuild margins. Management now expects full year adjusted gross margin below 50% after carving out a higher margin unit and flagging duplicate hosting and migration costs. The stock’s 25% drop after earnings suggests investors are treating these as missed milestones rather than temporary noise.

After a 25% one day share price fall and ongoing losses, it is worth asking if these setbacks are isolated or part of deeper structural issues. Review the independent risk analysis for Health Catalyst which shows 2 important warning signs to scan Health Catalyst for hidden operational and financial warning signs already flagged by our risk scoring.

Stay Ahead With Simply Wall St

If the 25% one day share price fall in Health Catalyst has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis develops. When you decide to take a position, use the Portfolio Command Center to cut through market noise and stay on top of the most important updates affecting your holdings. For a broader view on what other investors are thinking, tap into the Community and see how different perspectives line up with your own work. Spot potential catalysts or risks earlier and give yourself a better chance of staying ahead of the market.

Curious About Alternatives Beyond Health Catalyst

Fresh stock ideas can move fast once momentum builds and early buyers get in. Spot potential breakouts and under the radar stories before the crowd while it matters, act now.

• Chase potential breakout quality by reviewing a curated 19 high quality undiscovered gems that screens for stronger fundamentals while these stocks are still flying under most radars.
• Track shifting momentum in energy and infrastructure by scanning the 89 nuclear energy infrastructure stocks that highlights companies tied to long term power grid and reactor build out themes.
• Get ahead of capital flowing into hardware for AI by checking the 55 AI infrastructure stocks that focuses on companies supporting data centers, chips, and networking capacity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.